Grown Rogue International Valuation
Is GRIN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GRIN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate GRIN's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate GRIN's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GRIN?
Key metric: As GRIN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is GRIN's PE Ratio? | |
|---|---|
| PE Ratio | 40.6x |
| Earnings | US$3.86m |
| Market Cap | US$148.62m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.8x |
| Enterprise Value/EBITDA | 29.9x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does GRIN's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.3x | ||
RX BioSyent | 17.9x | n/a | CA$128.7m |
CPH Cipher Pharmaceuticals | 15.8x | 12.7% | CA$325.2m |
MDP Medexus Pharmaceuticals | 15.5x | 55.2% | CA$50.3m |
HASH Simply Solventless Concentrates | 64.2x | n/a | CA$55.1m |
GRIN Grown Rogue International | 40.6x | n/a | CA$208.9m |
Price-To-Earnings vs Peers: GRIN is expensive based on its Price-To-Earnings Ratio (40.6x) compared to the peer average (28.3x).
Price to Earnings Ratio vs Industry
How does GRIN's PE Ratio compare vs other companies in the North American Pharmaceuticals Industry?
| 14 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 14 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: GRIN is expensive based on its Price-To-Earnings Ratio (40.6x) compared to the North American Pharmaceuticals industry average (19.7x).
Price to Earnings Ratio vs Fair Ratio
What is GRIN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 40.6x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate GRIN's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Medexus Pharmaceuticals
CA$50.3m
Operates as a pharmaceutical company in Canada and the United States.
MDP
CA$2.03
7D
-7.7%
1Y
16.7%
Verano Holdings
CA$949.4m
Operates as a vertically integrated multi-state cannabis operator in the United States.
VRNO
CA$2.53
7D
-10.0%
1Y
-54.5%
Decibel Cannabis
CA$33.2m
An integrated cannabis company, engages in the cannabis cultivation, processing, and sale of cannabis flower products in Canada.
DB
CA$0.07
7D
-6.7%
1Y
-51.7%